Physician profile
Daniel J Cyran
NPI 1578569125
$1,322.10
in general payments reported to CMS, 2019-2025
16 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2022: $209 · 2023: $420 · 2024: $249 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.52 | 2022-2025 | Ubrelvy, Linzess, Viberzi |
| Novartis Pharmaceuticals Corporation | $309.91 | 2019-2024 | |
| Novo Nordisk INC | $225.52 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $159.02 | 2022-2025 | Trelegy Ellipta |
| Abbott Laboratories | $64.31 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $38.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.59 | 2025 | Spravato |
| Exact Sciences Corporation | $28.36 | 2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $20.84 | 2024 | Aplenzin |
| Dexcom, INC. | $19.97 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $17.82 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $14.25 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.03 | 2019 | |
| Esperion Therapeutics, INC. | $12.92 | 2023 | Nexletol |
| Amgen INC. | $12.83 | 2023 | Repatha, Otezla |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cyran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.